comparison of sedation between propofol and etomidate in patients with elective urological surgery

Clinical trial comparison of sedation and hemodynamic effects between propofol and etomidate in urological patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015082022734N1

Enrollment

177

Registered

2015-10-15

Start date

2013-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urological disease. Calculus in urethra

Interventions

Intervention 1: Etomidate will be injected intravenously by dose of 0.1 mg/kg, when inadequate response another 0.05 mg/kg will be injected. Intervention 2: Propofol will be injected intravenously by

Treatment - Drugs

Etomidate will be injected intravenously by dose of 0.1 mg/kg, when inadequate response another 0.05 mg/kg will be injected

Propofol will be injected intravenously by dose of 1 mg/kg, when inadequate response another 0.5 mg/kg will be injected

Eligibility

Sex/Gender

All

Age

50 Years to 90 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: patients with ambulatory elective urological surgery; age more than 50; ASA class I , II exclusion criteria: history of adrenal insufficiency; history of vital sign instability; history of allergy to the Etomidate or Propofol

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sedative effects. Timepoint: every 5 minute until 30 minute. Method of measurement: questionaire.	—

Secondary

Measure	Time frame
Vital signs. Timepoint: every 5 minute until 30 minute. Method of measurement: questionaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hamideh Yousefnezhad

Tehran University of Medical Sciences

mahshidyousefnezhad@gmail.com+98 11 3325 9115

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026